A Benefit-Risk Assessment of Imatinib in Chronic Myeloid Leukaemia and Gastrointestinal Stromal Tumours
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Toxicology
Reference59 articles.
1. Oncogenic kinase signalling
2. Targeted cancer therapy
3. The development of imatinib as a therapeutic agent for chronic myeloid leukemia
4. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
5. BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Evaluation of oxidative stress responses in human circulating blood cells after imatinib mesylate treatment – Implications to its mechanism of action;Saudi Pharmaceutical Journal;2019-12
2. Development and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients;PLOS ONE;2019-11-19
3. Biocompatible, pH-responsive, and biodegradable polyurethanes as smart anti-cancer drug delivery carriers;Reactive and Functional Polymers;2018-06
4. pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis;JCI Insight;2018-05-03
5. Combined cyto/genotoxic activity of a selected antineoplastic drug mixture in human circulating blood cells;Chemosphere;2016-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3